top of page
Genetic and Genomic Testing in Thyroid Cancer: Why, when, who and how?

Genetic and Genomic Testing in Thyroid Cancer: Why, when, who and how?

Play Video

Genetic and Genomic Testing in Thyroid Cancer: Why, when, who and how?

August 26th, 2020


Bryan McIver, MD, PhD

Deputy Physician-in-Chief

Moffitt Cancer Center

Dr. McIver received his MB ChB degree from the University of Edinburgh Medical School in Scotland, following undergraduate work in Edinburgh and a PhD in Physiology and Biophysics at the University of Vermont. He completed an Internal Medicine Residency at the Royal Infirmary of Edinburgh, followed by a Clinical Fellowship and Clinical Investigator Fellowship in Endocrinology at the Mayo Graduate School of Medicine in Rochester, MN.

Dr. McIver joined the staff of Mayo Clinic in 1998 and spent 15 years as a Consultant in
Endocrinology and Internal Medicine at the Mayo Clinic and Foundation, with 7 of those years as Chairman of the Mayo Clinic Thyroid Group. In 2011, he was appointed as a founder member of the Endowed and Master Clinician Program at the Mayo Clinic in Rochester, Minnesota, recognizing excellence in patient care. In 2013, he moved to Moffitt Cancer Center, to become the Program Leader of the Endocrine Tumor Program. His success in team-building led to an appointment as Interim Chair of Moffitt’s newly created Department of Head and Neck, and Endocrine Oncology. He subsequently assumed leadership responsibility as the Interim Chair of the Department of Breast Oncology, pending recruitment of a new Department Chair, and has played similar roles for the Departments of GI Oncology, Precision Oncology and Blood and Marrow Transplant and Cellular Immunotherapy. He was appointed Deputy Physician in Chief of the Moffitt Medical Group in 2015. In this role, he is responsible for Oncology clinical practice, including an employed group of over 300 Physicians and 250 Advanced Practice Professionals.

During his more than 20 years of clinical practice, Dr. McIver has gained broad experience in the evaluation and management of patients with thyroid nodules and cancer, with a particular focus on advanced and aggressive forms of thyroid cancer. He has a long-standing basic and translational research interest in the genetic regulation of growth, invasion and spread of thyroid tumors of all types. His primary research focus is the use of genetic and molecular techniques to improve the accuracy of diagnosis of thyroid nodules; more accurately predict outcomes in the disease; tailor targeted treatment to a patient’s unique needs; and guide the use of novel therapies for progressive and life-threatening disease.


Dr. McIver received two Mayo Clinic “Teacher of the Year” awards, recognizing his commitment to education of medical students, residents, and fellows. He is a founding member of the World
Congress on Thyroid Cancer, a biennial International meeting, now the largest such meeting in the world.


Testing for RET is provided by Lighthouse, a Celerity Biosciences Subsidiary, and Funded by Loxo Oncology at Lilly

bottom of page